The present invention relates to anti-VP 1 antibodies, antibody fragments, and their uses for the prevention and treatment of polyoma virus infection and associated diseases.

The present invention relates to multispecific antibodies, methods for their production, pharmaceutical compositions containing said antibodies and uses thereof.

The present disclosure relates to antibody conjugates with binding specificity for BCMA (BCMA) and its isoforms and homologs, and compositions comprising the antibody conjugates, including pharmaceutical compositions. Also provided are methods of producing the antibody conjugates and compositions as well as methods of using the antibody conjugates and compositions, such as in therapeutic and diagnostic methods.

Described are antibodies that specifically bind to the Axl protein and inhibit the interaction between Axl and the Axl-ligand, Gas6. Also disclosed are methods for the production and use of the anti-Axl antibodies.

A method for encrypting a video stream in a video encoder is provided that includes receiving the video stream and encrypting randomly selected pictures in the video stream as the video stream is encoded.

The present invention provides antagonizing antibodies that bind to complement factor D (CFD), conjugates thereof, and methods of using same. The anti-CFD antibodies can be used therapeutically alone or in combination with other therapeutics to treat age related macular degeneration and other diseases.

The present invention provides a novel antibody-pyrrolodiazepine derivative and a novel antibody-pyrrolodiazepine derivative conjugate using the same, and a novel CLDN6 and/or CLDN9 antibody.

The present invention provides novel antibodies and antigen binding fragments thereof that bind to human CD30. Also presented are single chain variable antibodies, chimeric antigen receptors and uses thereof. Methods of treating cancer are also disclosed.

Described herein are methods of treating, diagnosing, and/or prognosing a disease in a subject relating to detection of the glycosylation state of the antibodies present in the subject. In some embodiments, the disease can be an infection. In some embodiments, an antibody glycosylation state that is indicative of the presence of a disease, or a need for treatment of a disease can be reduced glycosylation (e.g., galactosylation, sialation, fucosylation, and/or afucosylated branched glycoforms).

The present application discloses variants of Pertuzumab. In particular, it discloses: an unpaired cysteine variant comprising Cys23/Cys88 unpaired cysteines in one or both variable light domains of Pertuzumab, an afucosylated variant of Pertuzumab, a low-molecular-weight-species (LMWS) of Pertuzumab, and a high-molecular-weight-species (HMWS) or Pertuzumab. The application further discloses the isolated variants, compositions, pharmaceutical compositions, and articles of manufacture comprising the variants, as well as methods of making and characterizing the variants and compositions thereof.